Lithium Shows Promise in Slowing Mild Cognitive Impairment (MCI) – Study Results

A recent randomized, double-blind, placebo-controlled trial conducted at the University of Pittsburgh School of Medicine has yielded encouraging, though not definitive, results regarding the potential of low-dose lithium carbonate in slowing cognitive decline associated with mild cognitive impairment (MCI). The study, which ran from February 2018 to August 2024 and followed participants for two years, found that while verbal memory declined at a slower rate in the lithium group compared to placebo, the difference did not reach statistical significance. This research adds to a growing body of evidence exploring lithium’s neuroprotective properties, particularly in relation to Alzheimer’s disease, but underscores the require for larger, more robust trials.

Study Design and Participant Characteristics

The LATTICE (Lithium as a Treatment to Prevent Impairment of Cognition in Elders) study involved 80 participants aged 60 and older diagnosed with MCI. Participants were randomly assigned to receive either daily low-dose lithium carbonate or a placebo. The average daily dose of lithium carbonate administered was 195mg, resulting in an average blood lithium level of 0.17 mmol/L. Researchers carefully monitored participants for safety and tolerability, and the study confirmed that low-dose lithium was generally well-tolerated by older adults. More details about the study design and initial findings were published in JAMA Neurology on March 5, 2026.

Mild Cognitive Impairment and the Lithium Hypothesis

Mild cognitive impairment represents a transitional stage between normal age-related cognitive changes and dementia. Individuals with MCI may experience problems with memory, language, or thinking skills, but these difficulties are not severe enough to interfere significantly with daily life. However, MCI increases the risk of developing dementia, including Alzheimer’s disease.

The investigation into lithium’s potential benefits stems from observations that lithium deficiency may play a role in the development of Alzheimer’s disease. Research suggests that amyloid plaques, a hallmark of Alzheimer’s, can sequester lithium, potentially disrupting its neuroprotective functions. As outlined in the study published in PubMed, the objective was to examine the feasibility, safety, and preliminary efficacy of lithium carbonate for delaying cognitive decline in older adults with MCI. While previous studies have hinted at a protective effect of lithium against dementia, this was the first randomized clinical trial to combine cognitive assessment, neuroimaging, and plasma biomarker analysis to rigorously test this hypothesis in humans.

Key Findings and Limitations

The LATTICE study assessed six pre-specified primary outcomes, including cognitive performance (specifically verbal memory and visuospatial memory), hippocampal volume, cortical gray matter volume, and levels of brain-derived neurotrophic factor (BDNF), a protein that supports the growth and survival of brain cells. None of these outcomes reached the pre-defined statistical significance threshold. However, a notable trend emerged in the verbal memory assessment. Participants receiving lithium experienced a slower rate of decline in verbal memory scores – a decline of 0.73 points annually compared to 1.42 points in the placebo group (a difference of 0.69 points per year, with a p-value of 0.05). While this difference suggests a potential benefit, it fell just short of statistical significance.

It’s crucial to acknowledge the limitations of this study. As the researchers themselves emphasize, LATTICE was designed as a pilot-feasibility trial, not a definitive test of lithium’s efficacy. The sample size of 80 participants was relatively small, which limited the study’s statistical power to detect subtle differences between the groups. The study enrolled participants with MCI but did not confirm the presence of underlying Alzheimer’s pathology using blood-based biomarkers. Information about the study’s design and aims can be found on ClinicalTrials.gov.

What Does This Indicate for Individuals with MCI?

The findings from the LATTICE study do not support the routine use of low-dose lithium carbonate as a treatment for MCI at this time. Individuals experiencing cognitive changes should consult with a qualified healthcare professional for a comprehensive evaluation and personalized management plan. There are currently no proven therapies to prevent or reverse cognitive decline in MCI, but lifestyle interventions such as regular exercise, a healthy diet, and cognitive stimulation may help to maintain cognitive function.

It’s important to understand the distinction between correlation and causation. While the study observed a trend towards slower verbal memory decline in the lithium group, this does not necessarily mean that lithium *caused* the improvement. Other factors, such as chance or unmeasured variables, could have contributed to the observed difference.

Next Steps in Lithium Research and Cognitive Health

Despite the lack of definitive proof, the LATTICE study provides valuable insights that will inform future research. The researchers have identified key methodological considerations and effect size estimates needed to design a larger, adequately powered confirmatory trial. Future trials should prioritize enrolling participants with confirmed Alzheimer’s pathology using blood-based biomarkers to better target the intervention to those most likely to benefit.

The ongoing investigation into lithium’s potential role in preventing dementia highlights the complexity of cognitive health and the need for continued research. Public health surveillance efforts will continue to monitor the incidence and prevalence of MCI and dementia, and researchers will explore novel therapeutic strategies to address this growing public health challenge. Individuals concerned about their cognitive health should stay informed about the latest research findings and discuss any concerns with their healthcare provider.